Form 4 for IMVT Immunovant, Inc.
Accepted 2024-12-04 00:00:00 ET · period of report 2024-12-02 · accession 0001764013-24-000200 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-04 | 2024-12-02 | IMVT | Pande Atul | Dir | S - Sale | $28.54 | -7,750 | 86.7K | -8% | -$221.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-02 | S | D | 7,750 | $28.54 | 86,663 | D | — | — | (F1) The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.03 - $29.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |